These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14532156)

  • 1. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology.
    Pelletier JP; Martel-Pelletier J
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii79-82. PubMed ID: 14532156
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets.
    Pelletier JP; Martel-Pelletier J; Abramson SB
    Arthritis Rheum; 2001 Jun; 44(6):1237-47. PubMed ID: 11407681
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis.
    Pelletier JP
    Osteoarthritis Cartilage; 2004; 12 Suppl A():S63-8. PubMed ID: 14698646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription of glucosamine for osteoarthritis: does it work and is it safe?
    Wollheim FA
    Nat Clin Pract Rheumatol; 2007 Jul; 3(7):364-5. PubMed ID: 17534290
    [No Abstract]   [Full Text] [Related]  

  • 5. Future therapeutics for osteoarthritis.
    Martel-Pelletier J; Wildi LM; Pelletier JP
    Bone; 2012 Aug; 51(2):297-311. PubMed ID: 22037003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-of-the-art disease-modifying osteoarthritis drugs.
    Moskowitz RW; Hooper M
    Curr Rheumatol Rep; 2005 Mar; 7(1):15-21. PubMed ID: 15760576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoarthritis in 2012: Parallel evolution of OA phenotypes and therapies.
    Conaghan PG
    Nat Rev Rheumatol; 2013 Feb; 9(2):68-70. PubMed ID: 23296390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodology of clinical trials in hand osteoarthritis. Issues and proposals.
    Maheu E; Dreiser RL; Lequesne M
    Rev Rhum Engl Ed; 1995 Jun; 62(6 Suppl 1):55S-62S. PubMed ID: 7583183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy reduces periodontoid rheumatoid pannus formation.
    Robinson AJ; Taylor DH; Wright GD
    Rheumatology (Oxford); 2008 Feb; 47(2):225-6. PubMed ID: 18056149
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacologic therapy for osteoarthritis--the era of disease modification.
    Hunter DJ
    Nat Rev Rheumatol; 2011 Jan; 7(1):13-22. PubMed ID: 21079644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging in osteoarthritis trials: useful or just expensive?
    Pelletier JP; Martel-Pelletier J
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):76-7. PubMed ID: 19182813
    [No Abstract]   [Full Text] [Related]  

  • 12. Erosive osteoarthritis of the hand: clinical experience with anakinra.
    Bacconnier L; Jorgensen C; Fabre S
    Ann Rheum Dis; 2009 Jun; 68(6):1078-9. PubMed ID: 19435727
    [No Abstract]   [Full Text] [Related]  

  • 13. Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
    Eckstein F; Le Graverand MP
    Semin Arthritis Rheum; 2015 Dec; 45(3):251-6. PubMed ID: 26142321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying effects of TD-198946 on progressed osteoarthritis in a mouse model.
    Yano F; Ohba S; Hosaka Y; Saito T; Chung UI
    Ann Rheum Dis; 2014 Nov; 73(11):2062-4. PubMed ID: 25135252
    [No Abstract]   [Full Text] [Related]  

  • 15. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.
    Pelletier JP; Martel-Pelletier J; Raynauld JP
    Arthritis Res Ther; 2006; 8(2):206. PubMed ID: 16569256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatology mini focus.
    Scheinman RI
    Future Med Chem; 2012 Apr; 4(6):697-9. PubMed ID: 22530632
    [No Abstract]   [Full Text] [Related]  

  • 17. How can one develop disease-modifying drugs in osteoarthritis?
    Dougados M
    Curr Rheumatol Rep; 2005 Mar; 7(1):22-8. PubMed ID: 15760577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for disease modification in osteoarthritis.
    Abramson SB; Attur M; Yazici Y
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):304-12. PubMed ID: 16932709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-arthritic agents: progress and potential.
    Laev SS; Salakhutdinov NF
    Bioorg Med Chem; 2015 Jul; 23(13):3059-80. PubMed ID: 26014481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?
    Qvist P; Bay-Jensen AC; Christiansen C; Dam EB; Pastoureau P; Karsdal MA
    Pharmacol Res; 2008 Jul; 58(1):1-7. PubMed ID: 18590824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.